Comparing Prognosis Associated with Partial Cystectomy and Trimodal Therapy for Muscle-Invasive Bladder Cancer Patients

被引:3
|
作者
Su, Quanxin [1 ,2 ]
Gao, Shenglin [1 ]
Lu, Chao [1 ]
Wu, Xingyu [1 ]
Zuo, Li [1 ]
Zhang, Lifeng [1 ]
机构
[1] Nanjing Med Univ, Dept Urol, Affiliated Changzhou Peoples Hosp 2, Changzhou, Peoples R China
[2] Dalian Med Univ, Dept Grad Sch, Dalian, Peoples R China
关键词
Muscle-invasive bladder cancer; Bladder-sparing therapy; Prognosis; Propensity score model; LONG-TERM OUTCOMES; RADICAL CYSTECTOMY; UROTHELIAL CARCINOMA; NEOADJUVANT CHEMOTHERAPY; MANAGEMENT; PRESERVATION;
D O I
10.1159/000518562
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study aimed to compare the survival outcomes between trimodal therapy (TT) and partial cystectomy (PC) in muscle-invasive bladder cancer (MIBC) patients. Methods: The data of 13,096 patients with MIBC diagnosed between 2004 and 2015 were retrieved from the Surveillance, Epidemiology, and End Results database. Among them, 4,041 patients underwent TT and 1,670 patients underwent PC. Propensity score matching was performed to balance the characteristics between the 2 treatment groups. A multivariate Cox regression analysis model and a competing risk model were used to evaluate overall survival (OS) and cancer-specific survival. Cumulative incidence survival curves were obtained using the Kaplan-Meier method. Results: Results of multivariate Cox analysis before propensity score matching showed that the TT group had a 31% reduction in cause-specific survival relative to the PC group (HR: 0.69, 95% CI: 0.61-0.78, p < 0.001) and a 28% reduction in OS (HR: 0.72, 95% CI: 0.66-0.79, p < 0.001). After propensity score matching, the 2 groups yielded 972 patients, with 3-year cause-specific survival rates of 54.1% and 68.5% in the TT group and the PC group, respectively. Conclusions: Patients who underwent PC had a better prognosis than those who received TT. In addition, for MIBC patients who required bladder-sparing therapy, advanced age (>= 80 years), pathological type of squamous cell carcinoma, and tumor stage of T3-4, N2-3, and M1 were independent poor prognostic factors.
引用
收藏
页码:46 / 57
页数:12
相关论文
共 50 条
  • [31] Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis
    Kim, Yeon Joo
    Byun, Sang Jun
    Ahn, Hanjong
    Kim, Choung-Soo
    Hong, Beom-Sik
    Yoo, Sangjun
    Lee, Jae-Lyun
    Kim, Young Seok
    ONCOTARGET, 2017, 8 (40) : 68996 - 69004
  • [32] Long-term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.
    Golla, Vishnukamal
    Shan, Yong
    Farran, Elias Joseph
    Vu, Kevin
    Stewart, Courtney A.
    Khaki, Ali Raza
    Keegan, Kirk A.
    Kamat, Ashish M.
    Tyler, Douglas S.
    Freedland, Stephen J.
    Williams, Stephen B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [33] Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis
    Kool, Ronald
    Yanev, Ivan
    Hijal, Tarek
    Vanhuyse, Marie
    Cury, Fabio L.
    Souhami, Luis
    Kassouf, Wassim
    Dragomir, Alice
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2022, 16 (06): : 189 - 198
  • [34] Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer
    Ajib, Khaled
    Tjong, Michael C.
    Tan, Guan Hee
    Nason, Gregory
    Berjaoui, Mohammad Baker
    Erlich, Annette
    Maganti, Manjula
    Sridhar, Srikala
    Fleshner, Neil E.
    Zlotta, Alexandre R.
    Catton, Charles
    Berlin, Alejandro
    Chung, Peter
    Kulkarni, Girish S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (12): : 404 - 410
  • [35] COMPARATIVE EFFECTIVENESS OF TRIMODAL THERAPY VERSUS RADICAL CYSTECTOMY FOR LOCALIZED MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
    Seisen, Thomas
    Sun, Maxine
    Lipsitz, Stuart R.
    Abdollah, Firas
    Leow, Jeffrey J.
    Menon, Mani
    von Landenberg, Nicolas
    Gild, Philipp
    Roupret, Morgan
    Preston, Mark
    Harshman, Lauren C.
    Kibel, Adam S.
    Nguyen, Paul L.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Trinh, Quoc-Dien
    JOURNAL OF UROLOGY, 2017, 197 (04): : E1197 - E1198
  • [36] Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder
    Seisen, Thomas
    Sun, Maxine
    Lipsitz, Stuart R.
    Abdollah, Firas
    Leow, Jeffrey J.
    Menon, Mani
    Preston, Mark A.
    Harshman, Lauren C.
    Kibel, Adam S.
    Nguyen, Paul L.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Quoc-Dien Trinh
    EUROPEAN UROLOGY, 2017, 72 (04) : 483 - 487
  • [37] Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review
    Ploussard, Guillaume
    Daneshmand, Siamak
    Efstathiou, Jason A.
    Herr, Harry W.
    James, Nicholas D.
    Roedel, Claus M.
    Shariat, Shahrokh F.
    Shipley, William U.
    Sternberg, Cora N.
    Thalmann, George N.
    Kassouf, Wassim
    EUROPEAN UROLOGY, 2014, 66 (01) : 120 - 137
  • [38] PROGNOSIS AFTER RADICAL CYSTECTOMY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER DOWNSTAGED BY TRANSURETHRAL RESECTION OF BLADDER TUMOR
    Kim, Kwang Hyun
    You, Dalsan
    Moon, Kyung Hyun
    Ji, Young Hwan
    Jeong, In Gab
    Song, Cheryn
    Hong, Jun Hyuk
    Ahn, Hanjong
    Ahn, Tai Young
    Kim, Choung-Soo
    JOURNAL OF UROLOGY, 2011, 185 (04): : E197 - E198
  • [39] RADICAL CYSTECTOMY PROVIDES IMPROVED SURVIVAL OUTCOMES AND DECREASED COSTS COMPARED WITH TRIMODAL THERAPY FOR PATIENTS DIAGNOSED WITH LOCALIZED MUSCLE-INVASIVE BLADDER CANCER
    Williams, Stephen
    Kosarek, Christopher
    Shan, Yong
    Jazzar, Usama
    Mehta, Hemalkumar
    Baillargeon, Jacques
    Huo, Jinhai
    Senagore, Anthony
    Orihuela, Eduardo
    Tyler, Douglas
    Swanson, Todd
    Kamat, Ashish
    JOURNAL OF UROLOGY, 2018, 199 (04): : E235 - E236
  • [40] Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer
    Marcq, Gautier
    Souhami, Luis
    Cury, Fabio L.
    Salimi, Afsar
    Aprikian, Armen
    Tanguay, Simon
    Vanhuyse, Marie
    Rajan, Raghu
    Brimo, Fadi
    Mansure, Jose Joao
    Kassouf, Wassim
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (03): : 738 - 741